Table 1 Patient baseline characteristics of combination and monotherapy groups before and after PSM

From: Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Characteristics

Before PSM

After PSM

Combination group (n = 376)

Monotherapy group (n = 450)

P-value*

Combination group (n = 228)

Monotherapy group (n = 228)

P-value*

Median age (years)

55 (49–65)

61 (54–69)

<0.001

57 (50–67)

57 (50–66)

0.874

Sex

  

0.911

  

>0.999

 Male

317 (84.3)

377 (83.8)

 

190 (83.3)

191 (83.8)

 

 Female

59 (15.7)

73 (16.2)

 

38 (16.7)

37 (16.2)

 

Etiology

  

0.480

  

0.834

 Hepatitis B virus

288 (76.6)

334 (74.2)

 

163 (71.5)

166 (72.8)

 

 Others

88 (23.4)

116 (25.8)

 

65 (28.5)

62 (27.2)

 

Cirrhosis

  

<0.001

  

>0.999

 Yes

281 (74.7)

279 (62.0)

 

166 (72.8)

166 (72.8)

 

 No

95 (25.3)

171 (38.0)

 

62 (27.2)

62 (27.2)

 

Child-Pugh class

  

0.232

  

0.516

 A

312 (83.0)

388 (86.2)

 

196 (86.0)

190 (83.3)

 

 B

64 (17.0)

62 (13.8)

 

32 (14.0)

38 (16.7)

 

ECOG PS

  

<0.001

  

0.751

 0

248 (66.0)

372 (82.7)

 

165 (72.4)

169 (74.1)

 

 1

128 (34.0)

78 (17.3)

 

63 (27.6)

59 (25.9)

 

BCLC stage

  

<0.001

  

>0.999

 B

103 (27.4)

226 (50.2)

 

78 (34.2)

77 (33.8)

 

 C

273 (72.6)

224 (49.8)

 

150 (65.8)

151 (66.2)

 

Up-to-seven

  

0.662

  

0.913

 ≤7

91 (24.2)

102 (22.7)

 

55 (24.1)

57 (25.0)

 

 >7

285 (75.8)

348 (77.3)

 

173 (75.9)

171 (75.0)

 

Macroscopic portal vein invasion

  

<0.001

  

0.778

 Absent

192 (51.1)

293 (65.1)

 

124 (54.4)

120 (52.6)

 

 Present

184 (48.9)

157 (34.9)

 

104 (45.6)

108 (47.4)

 

Extrahepatic spread

  

<0.001

  

>0.999

 Absent

223 (59.3)

351 (78.0)

 

152 (66.7)

152 (66.7)

 

 Present

153 (40.7)

99 (22.0)

 

76 (33.3)

76 (33.3)

 

TACE type

  

0.440

  

0.396

 cTACE

279 (74.2)

322 (71.6)

 

163 (71.5)

172 (75.4)

 

 DEB-TACE

97 (25.8)

128 (28.4)

 

65 (28.5)

56 (24.6)

 

HCC-related treatment history

  

<0.001

  

0.841

 Absent

180 (47.9)

378 (84.0)

 

154 (67.5)

157 (68.9)

 

 Present

196 (52.1)

72 (16.0)

 

74 (32.5)

71 (31.1)

 

  Surgery

62 (16.5)

32 (7.1)

<0.001

27 (11.8)

31 (13.6)

0.674

  TACE

165 (43.9)

46 (10.2)

<0.001

61 (26.8)

46 (20.2)

0.122

  Ablation

35 (9.3)

18 (4.0)

0.002

14 (6.1)

18 (7.9)

0.583

  Radiotherapy

38 (10.1)

8 (1.8)

<0.001

15 (6.6)

8 (3.5)

0.198

  1. Data are median (interquartile range) or n (%)
  2. PSM propensity score matching, ECOG PS Eastern Cooperative Oncology Group performance status, BCLC Barcelona Clinic Liver Cancer, TACE transarterial chemoembolization, cTACE conventional transarterial chemoembolization, DEB-TACE drug-eluting beads transarterial chemoembolization, HCC hepatocellular carcinoma
  3. *Mann–Whitney U and the Student’s t test for continuous variables and Chi-squared test or Fisher exact test for categorical variables were applied
Back to article page